BRL-50481

Details

Stereochemistry	ACHIRAL
Molecular Formula	C9H12N2O4S
Molecular Weight	244.268
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)S(=O)(=O)C1=CC(=CC=C1C)[N+]([O-])=O

InChI

InChIKey=IFIUFCJFLGCQPH-UHFFFAOYSA-N

InChI=1S/C9H12N2O4S/c1-7-4-5-8(11(12)13)6-9(7)16(14,15)10(2)3/h4-6H,1-3H3

HIDE SMILES / InChI

Molecular Formula	C9H12N2O4S
Molecular Weight	244.268
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18420479 | https://www.ncbi.nlm.nih.gov/pubmed/19033455 | https://www.ncbi.nlm.nih.gov/pubmed/15371556

BRL-50481 is a selective inhibitor of phosphodiesterase 7 (PDE 7) that has acceptable selectivity for in vitro studies. Studies suggest that BRL-50481 is used to inhibit the activity of hrPDE7A1 which is usually expressed in baculovirus-infected Spodoptera frugiperda in a competitive manner. In osteoblasts, BRL-50481increases mineralization and bALP as a result of PDE7 silencing which upregulates several osteogenic genes. Further studies show that BRL-50481increases apoptosis in CLL cells via a mitochondrial-dependent process, and is associated with increased cAMP accumulation and down-regulation of the antiapoptotic protein survivin. BRL-50481 is a inhibitor of PDE7A.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Phosphodiesterase 7A 1 Target ID: CHEMBL3012 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15371556	Inhibitor 8297		180.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Anxiety 267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27864049	Primary		Preclinical	Unknown Approved Use Unknown
Osteoporosis 97 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18420479	Primary		Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes.	2004 Dec	15371556
New classes of PDE7 inhibitors identified by a fission yeast-based HTS.	2010 Apr	20228279

Patents

Sample Use Guides

In Vivo Use Guide

Rats: accumbal injection of 4ug/0.3uL of BRL-50481 decreased rats' anxiety. The i.p. injection of 0.2mg/kg of BRL-50481 was able to increase the PVN TRH mRNA expression and to decrease feeding but did not change animals' anxiety levels; in contrast, 2mg/kg b.w BRL-50481 enhanced accumbal TRH mRNA, induced anxiolysis with no change in food intake.

Route of Administration: Intraperitoneal

In Vitro Use Guide

At substrate concentrations of 50 nM and 1 uM, BRL-50481 inhibited the hydrolysis of cAMP by hrPDE7A1 with IC50 values of 0.26 and 2.4 uM, respectively. BRL-50481 failed to significantly inhibit PDE1B, PDE1C, PDE2, and PDE5 at concentrations below 100 uM. BRL-50481 suppressed, in a concentration-dependent manner, LPS-induced TNF release in human monocytes in which PDE7A1 was induced (21.7 1.6% inhibition at 30 uM at the 12-h time point).

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:31:00 GMT 2023` Edited by `admin` on `Sat Dec 16 08:31:00 GMT 2023`
Record UNII	03G869PR3P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BRL-50481

Common Name

English

BENZENESULFONAMIDE, N,N,2-TRIMETHYL-5-NITRO-

Systematic Name

English

Code System Code Type Description

EPA CompTox

DTXSID30195832